DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Sepsis - Pipeline Review, H2 2016" report to their offering.
This report provides comprehensive information on the therapeutic development for Sepsis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sepsis and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Mentioned:
- Adrenomed AG
- Altor BioScience Corporation
- Am-Pharma B.V.
- Arch Biopartners, Inc.
- Aridis Pharmaceuticals LLC
- Asahi Kasei Pharma Corp.
- Astellas Pharma Inc.
- Batu Biologics, Inc.
- Biomedica Management Corporation
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Cell2B S.A.
- Chiesi Farmaceutici SpA
- Chiome Bioscience, Inc.
- Cilian AG
- Cognosci, Inc.
- Cytheris SA
- Endacea, Inc.
- Evec, Inc.
- Huons Co., Ltd.
- (25+ Others)
Key Topics Covered:
- Introduction
- Sepsis Overview
- Therapeutics Development
- Pipeline Products for Sepsis - Overview
- Pipeline Products for Sepsis - Comparative Analysis
- Sepsis - Therapeutics under Development by Companies
- Sepsis - Therapeutics under Investigation by Universities/Institutes
- Sepsis - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Sepsis - Products under Development by Companies
- Sepsis - Products under Investigation by Universities/Institutes
- Sepsis - Companies Involved in Therapeutics Development
For more information about this report visit http://www.researchandmarkets.com/research/z43m9k/sepsis_pipeline
